EUVIMEDEUVIMED entdecken
Crossref

C ‐5‐Arylidene‐Thiazolidine‐2,4‐Dione Analogs Against Aldose Reductase: Design, Synthesis, Biological Evaluation, and Computational Insights

Rajiv Patel iD, Sanjeev Ranjan, Nandini, Anwesha Das, Arijit Nandi iD, Sant Kumar Verma iD

Archiv der Pharmazie · 2025-11 · 358 (11)

DOI: 10.1002/ardp.70159 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, online erschienen am 29.11.2025. Verfasst von Rajiv Patel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Ghal Kalan, Punjab, India. Hauptthemen laut MEDLINE: Aldehyde Reductase, Thiazolidinediones, Drug Design, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetic complications are major health problems that happen to people with diabetes when their blood sugar levels stay high for a long time and damage various body organs and systems. Inhibition of aldose reductase has emerged as a promising strategy for drug development and the management of diabetes‐associated complications. In the research article, a novel series of 12 compounds, “ C −5‐arylidene thiazolidine‐2,4‐dione derivatives” was constructed, synthesized, and characterized using both spectral and non‐spectral techniques. The confirmed synthesized compounds were subsequently screened for in vitro aldose reductase inhibitory activity. Among them, compounds 9h and 9a exhibited superior potency against aldose reductase protein with IC 50 values of 0.98 and 1.05 µM, respectively, as compared with the reference drug epalrestat (IC 50 value of 1.20 µM). Additionally, compounds 9l and 9i showed moderate aldose reductase inhibitory activity with an IC 50 value of 1.36 and 2.47 µM, respectively. Furthermore, the top four best active compounds were selected for in vivo anti‐hyperglycaemic activity. Results revealed that all the tested compounds significantly decreased blood glucose levels at all time intervals. Computational analysis revealed that all synthesized candidates bound firmly in the protein cavity of aldose reductase via hydrogen bonds and steric interaction with the range of docking score −10.21 to −11.81 kcal/mol. Predicted in silico toxicity data suggested that the synthesized compounds were inactive and nontoxic against peroxisome proliferator‐activated receptor‐γ protein. These finding results support the potential of thiazolidine‐2,4‐dione derivatives as promising AR inhibitors for managing diabetic complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aldehyde ReductaseThiazolidinedionesDrug DesignHypoglycemic AgentsEnzyme InhibitorsStructure-Activity RelationshipMolecular Docking SimulationAnimalsMolecular StructureDose-Response Relationship, DrugDiabetes Mellitus, ExperimentalMaleRatsHumansBlood Glucose

Stichwörter der Autor:innen

aldose reductaseanti‐hyperglycaemicdiabetes mellitusin silico toxicitymolecular dynamicsthiazolidine‐2,4‐dione

Substanzen

Aldehyde ReductaseThiazolidinedionesHypoglycemic Agentsthiazolidine-2,4-dioneEnzyme InhibitorsBlood Glucose

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Ghal Kalan, Punjab, India.
  • Amity Institute of Pharmacy, Amity University Uttar Pradesh, Noida, India.
  • Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research, S.A.S. Nagar, Punjab, India.
  • School of Pharmacy, Sharda University, Greater Noida, Uttar Pradesh, India.
  • Department of Pharmacy, Sanaka Educational Trust Group of Institutions (SETGOI), Durgapur, West Bengal, India.
  • School of Pharmacy and Pharmaceutical Sciences, The University of Queensland, Brisbane, Queensland, Australia.

ORCID-Profile: Rajiv Patel, Arijit Nandi, Sant Kumar Verma

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Patel, R., Ranjan, S., Nandini, Das, A., Nandi, A., & Verma, S. K. (2025). C ‐5‐Arylidene‐Thiazolidine‐2,4‐Dione Analogs Against Aldose Reductase: Design, Synthesis, Biological Evaluation, and Computational Insights. Archiv der Pharmazie, 358(11). https://doi.org/10.1002/ardp.70159

Vancouver

Patel R, Ranjan S, Nandini, Das A, Nandi A, Verma SK. C ‐5‐Arylidene‐Thiazolidine‐2,4‐Dione Analogs Against Aldose Reductase: Design, Synthesis, Biological Evaluation, and Computational Insights. Archiv der Pharmazie. 2025;358(11). doi:10.1002/ardp.70159

BibTeX
@article{Patel2025,
  author = {Patel, Rajiv and Ranjan, Sanjeev and Nandini and Das, Anwesha and Nandi, Arijit and Verma, Sant Kumar},
  title = {C ‐5‐Arylidene‐Thiazolidine‐2,4‐Dione Analogs Against Aldose Reductase: Design, Synthesis, Biological Evaluation, and Computational Insights},
  journal = {Archiv der Pharmazie},
  year = {2025},
  volume = {358},
  number = {11},
  doi = {10.1002/ardp.70159}
}
Kostenlos starten →